抗CD20治疗性单克隆抗体的研究进展  

Advances in the research of anti-CD20 therapeutic monoclonal antibodies

作　　者：邓承莲[1,2] 邹佳[2] 宋海峰[2] 

机构地区：[1]广西医科大学,广西南宁530002 [2]军事医学科学院放射与辐射医学研究所,北京100850

出　　处：《药学学报》2013年第10期1515-1520,共6页Acta Pharmaceutica Sinica

摘　　要：作为治疗B细胞淋巴瘤的靶向药物,抗CD20单克隆抗体在治疗性抗体中占有重要的一席之地。经历十几年的研究发展,该类药物结构不断改进,适应症也随之增多。如今,该类抗体不仅可以用于治疗淋巴细胞来源的肿瘤,也逐步应用于一些自身免疫性疾病的治疗,其新型适应症还在不断探索中;同时,该类抗体临床给药方案不断优化,药物反应性不断提高,疗效和毒副作用都得以进一步改善,但和其他化疗药物联合治疗的确切作用机制尚仍有待进一步的深入研究。本文就近年来具有代表性的抗CD20治疗性单克隆抗体的研究新进展做一概述。As targeted drugs to B-cell malignancies, anti-CD20 monoclonal antibodies have been proved to be important in therapeutic antibody field. With three generations in more than ten years＇ development, the structures of these drugs have been improved, and many new indications have been found. Nowadays, these kinds of antibodies are not only used in the treatment of lymphoid malignancies, but also been proved to be useful in some autoimmune diseases treatment, and their new indications are still being expanded. With the optimization of their clinical dosage regimens, drug reaction has been increased, thus, therapeutic and side effects of anti-CD20 monoclonal antibody have been further improved as well. However, the exact mechanism of action of their combination therapy with other chemical drugs is still unclear, which remains to be further studied. This article reviewed new development of anti-CD20 therapeutic monoclonal antibodies research in recent years.

关 键 词：治疗性单克隆抗体 嵌合抗体 人源化抗体 人源抗体 Fc修饰 

分 类 号：R963[医药卫生—微生物与生化药学]